Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Excellent point. Also with three years of cash runway Anavex can halt sales of stock for two full years allowing the share price to gradually rise further disuading short sellers and when they do sell stock again, if ever, it should be at a much higher price.
Also it is not without precident for a pre- revenue biotech to approve a share buyback when they are flush with cash to counter short sellers. Without sufficient cash that shield is not available but rather at risk of shorts gaming the cash raise cycle.
Maybe Mother Superior jumped the gun?
Live by the trade die by the trade.
I think everyone has done their own due diligence and some had a higher value on the shares vs. the cash.
One can buy any other stock with cash it is not nessesary to complain about what was sold especially when in possession of biotech stock screening tools.
The fact that blarcamesine might also improve sleep and mood due to mild effects as a SSRI might result in result in truly blockbuster sales if approved for daily use as prophylaxis for .....
anything?
I believe Anavex patent protection is better than AMRN. I have not looked at AMRN patents but Anavex has a whole suite of patents which provide comprehensive protection IMO. An Anavex Director is a world class patent attorney in the area of pharmaceuticals.
The Coup de Gras of these is the patent on the crystalline form of A2-73 and it's isomers. This is the shelf stable form suitable for pills and no refrigeration. The FDA could not likely find a liquid generic form non-inferior because of the risk of degradation as it moves though the supply chain to the consumer. Also they would have a hard time competing on price as the drug is not expensive to make but the non stable form would be expensive to ship and handle, again with less confidence in a consistent product.
I believe icosapent ethyl (Vascepa) is non-crystalline and stable in its liquid form.
No patent issues at Anavex. Anavex management are practical Cats. Everything is planned and executed to precision.
Circuit breakers are bad news mostly bad news for longs. They will often cause a reversal off an upspike but not always.
You can add the fake MD Twitter handle @Midwesthedgie to the RICO Ring. Although after investigation I suspect Joseph J. Spiegel will be identified as the fake MD. There can not be many that stupid. I am curious about the connections to the Howard Beach Queens nest.
I agree and not only that, Leronlimab was given a billing code. I believe it was the only one or a very select few that got billing code prior to at least a EUA or approval. Wall Street darling HGEN's drug did not even though it got Government funding and is also at the end of Phase 3.
The way Avavex is "Truckin" along now you might be safe to leave the risk on when you go cross-country free wheelin two-wheelin this summer. I am hands off AVXL now because it is already a 10 bagger for me don't want to pay the tax and I think it could be a 5 bagger further from here.
Actually Anavex is at the point in development of biotechs where usually take first positions. The lower infection concave curve in the classic S development curve. If it plays out like the others it should rise fairly steeply over the next 18-24 months. If Missling spares the stock sales going forward that alone should cause the price channel to steepen considerably. Seventy-one by twenty-twentythree. Anavex is following the same path as Arrowhead did just about 24 months ahead.
Anavex the whole 6-year "trip" since Missling took over if it were a song. (Or hairstyle)
What a long strange trip it been, some got their chips cashed in,
sometimes the lights are all shining on me other times we could barely see!
Ok I get it. Has nothing to do with cbdMD just that Adara CEO was or is also an Executive at cbdMD.
Hello just started investing here in YCBD what is purpose of the Adara spac?
That would indeed be welcome for us net accumulators.
AVXL is currently at the inflection point in is multiyear chart. Take a look at ARWR and SAGE multiyear charts and compare. If AVXL follows these trajectories multibillion market cap is achievable in roughly 18 months. ARWR chart and development is strikingly similar to AVXL. At this point price and access to capital, as Froll aptly states is much more favorable so Missling can loosen the purse strings and spend more to speed developments on several fronts.
It is a fine line to follow between spending too much to fast and not spending enough. I think we will see accelerated development going forward.
Fidelity does its own clearing through Fidelity Clearing Corp. Other discount brokers sell the order flow. Fidelity offers full set of account types and good tools and education. #1 rated overall. I like the ThinkorSwim platform but execution is much better on Fidelity. I have both. I think some others here use Fidelity, there one gets interest on loaned shares TDA does not even inform customers when they are loaned out.
I wonder if the TDA platform was slowed down by the SNDL attempted gap and trap. It halted in the first 5 min with over 300 million traded first 5 min and 180 million the second 5 min. I watched it fill orders during the halt all at the 30 min 50 ma $2.76. Except a few lucky or unluckies at exactly $1. Must have been a Robinhoodulum stop loss order. Haha
The gap and trap was of little success as stock is still above yesterday's close of $2.95 with 1.3 billion shares traded already out of 1.5 billion outstanding shares.
I have never seen that type of crazy volume in AVXL but we did have some crazy days in 2015 and 2016.
No news of course drove that trade just gamma rebalance on insane otm options volume yesterday and momo in the weed sector.
There are plenty of potential catalysts near term. That is as nonsensical as conflating the Biotech sector with the Health Care sector.
The report reads like Cowan found some buyers on the run up. So that is all I need to know about big investors wanting in.
If AVXL sells off today it will be because Wall Street wants to accumulate.
Ok thanks. Now that all makes sense. Discretionary.
Steady I think you accidently wrote that wrong. The definition of "Elective Surgery" is those surgeries NOT Covered by Insurance per the terms of each policy. (If I am not mistaken )
Biogen has been very active lately. There MO of late has been to do a partnership and take a 10% stock stake. The last one was with SAGE they paid $106 for the newly issued shares when SAGE was trading at $86. BTW Wall Street poo pooed that excellent deal and wash traded to down to $68 over the next week or so while the Absurd Wall Street Analysts publicly downgraded SAGE. I pointed it out at the time that that was proof Wall Street say one thing and sells good news so they can accumulate lower. I bought the low $70s and sold in the mid $90s just a few weeks later on the cue that Wall Street started upgrading SAGE signaling as it were that Wall Street had finished accumulating on the cheap and were ready to distribute the now inflated shares to the public.
Before that they did a partnership with a 10% stock deal with Denali for the ALZ drug. I am not invested in that one.
So I would not be surprised to see a partnership with Anavex with a 10% stock stake. Anavex has the 10 million preferred which would be a non voting way to do it.
But if that happens be prepared for AVXL stock to sell off for a few weeks before it goes up.
Denali did not sell off, it when up, which tells me Wall Street had enough DNLI shares and wanted to sell rather than accumulate.
Denali did an IPO Anavex did not. So AVXL will likely sell off hard while Wall Street accumulates THEN rise sharply when they are finished accumulating.
If one does not believe this is how it works I can only say look up the date of the BIIB/SAGE deal and see my posts the next day then look at the SAGE stock chart and Analyst upgrade/downgrades after that.
now is has 1/2 the market cap of Tilray
i awas thinging can not be right but that what is says nasdaq.com after hours qoute how many shares rtraded reg hours my brokerage says only 53 million
208 milion shares traded after hours according to masdaq.com
something up...serious fundamental
ARWR is a good one to compare. It traded in the single digits for years at just a few hundred million Market Cap. I jumped in at $13 and it went to $70 in less than 18 months.
Historically that would have been a good trade. I was thinking about selling covered as well until I saw that short squeezes were rolling through the market.
Yesterday there was a big squeeze in junior vaccine Biotechs when news came out about the AZN vaccine not being as effective on the So African strain. OCGN spiked 300% at one point. Minor news big effect.
99% of the time an Options market maker is the counterparty to an Options trade. They will not take the shares out of your account until they are needed to balance their market makeing operations. Being so deep in the money they should now trade with near zero time value. A net buyer will not exercise until later as now those in the money options provide leverage and they can use the cash they would need to exercise them to make other trades as there current value shows up in their accounts, they can not multiple for additional leverage unless they have portfolio margin or day trade margin privileges but still provide leverage same as non marginable securities.
Call your broker for advice what I say can not be taken as advice.
It is good that you will not take the position that AVXL will reach $10 before it reaches $20 because I think that is a losing proposition. AVXL will reach $20 before it retraces to $10. I make that call now as AVXL is trading at $14.78.
No I am not I said Biotech you said healthcare. You said that AVXL would retrace. I think it will go higher.
Biotech do you understand? I say AVXL reaches $20 before $10. What say you?
Health care includes hospitals and many others. I said Biotech. Specfically XBI and IBB.
I said Biotech not health care. So you agree that AVXL is more likely to reach $20 before it retraces to $10?
Well my analysis concludes differently.
AVXL is $15 half way between $10 and $20. It is often easier to retrace than continue to rise. Nevertheless I say AVXL reaches $20 before $10. I would presume you would take the opposite, correct?
So we shall see.
Reported short numbers only. Many or mostshort positions are never reported.
S3 attempts to get and approximation. Anything that is reported will be padding and not include the last run up days. Reported numbers are inaccurate and misleading most of the time.
You might be missing the fairly fluid sector rotation into biotech in your analysis.Take a look at the sector indexes. XBI and IBB are two that I watch.
Buying the dips
Will happen all the time.
For selling covered calls
Is past it's prime.
The Artful Dodger would never attempt to pick the pocket of a finely dressed gentleman on his way to the bank.
Organized Crime would never attempt looting and racketeering in the stock market. Everyone knows all the big money is held in the banks so the RICOs stick to the banks to ply their trade.
No pirates would sail their ships though the wide loophole passage in Regulation SHO to sieze the booty bound for the Liquidity Harbour.
That brings up a good point. I wonder if the Quarterly Report will disclose the results of the A3-71 phase 1 trial?
That is why I said a sale through Cantor would be a negotiated price. No one would buy at the peak or close to it. If an big investor wanted to take a position that very day they would likely enter a MOC order or a LOC order on the open market. The best price the company could get for newly issued shares would be the vwap or else the closing price. But usually they are made at some MA price. Cantor would also need time to negotiate the deal unless they had a buyer ready that wanted to buy a peak price. (HaHa)
Quote: "I hope Anavex sold shares above $15" I guess this is a common misperception. I have read a few messages similar. No company can issue shares on a day trade. AVXL has not closed above $15. LPC has a formula for lowest 10 day average. Cowen has to find a buyer for a negotiated price If the price stays at this higher channel for a number of days then Anavex might be able to issue shares at a higher price than earlier issues.
What I hope to see is that no insiders sold shares which I am confident they did not.